Perindopril: possible use in cancer therapy
作者:
Hitoshi Yoshiji,
Shigeki Kuriyama,
Hiroshi Fukui,
期刊:
Anti-Cancer Drugs
(OVID Available online 2002)
卷期:
Volume 13,
issue 3
页码: 221-228
ISSN:0959-4973
年代: 2002
出版商: OVID
关键词: Angiogenesis;angiotensin II;perindopril;vascular endothelial growth factor
数据来源: OVID
摘要:
Since angiogenesis is essential for the growth of any solid tumor, emerging efforts are being made to develop antiangiogenic therapy. To date, however, no antiangiogenic agent has become widely available for the clinical setting. Angiotensin I-converting enzyme (ACE) inhibitors are commonly used as antihypertensive agents and it has recently been suggested that they decrease the risk of cancer. Studies have found that an ACE inhibitor, perindopril, is a potent inhibitor of experimental tumor development and angiogenesis at a clinically comparable dose. The potent angiogenic factor, vascular endothelial growth factor (VEGF), is significantly suppressed by perindopril and also inhibits VEGF-induced tumor growth.In vitrostudies showed that perindopril is not cytotoxic to either tumor cells or endothelial cells. Since perindopril is already in widespread clinical use without serious side effects, it may represent a potential new strategy for anticancer therapy.
点击下载:
PDF
(149KB)
返 回